Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hlb Pharmaceutical Co. Ltd. operates within the Biotechnology & Pharmaceuticals technology area with a portfolio currently managing 1 pending office action. This single action is distributed across 1 distinct examiner and 1 distinct art unit, indicating a highly concentrated prosecution footprint. Such concentration suggests that the company's current legal challenges or applications are confined to a single point of contact within the patent office, rather than being spread across multiple specialized departments. This structure simplifies the administrative oversight required for the portfolio as there is only one set of examiner expectations to manage.
The busiest examiner for this portfolio is LEE, HOI YAN NMN, who is responsible for 1 pending action. This figure matches the total number of pending office actions for the company, confirming that no other examiners are currently reviewing active cases for this entity. The involvement of only 1 distinct art unit suggests that the technology being patented falls within a specific technical niche. Practitioners should focus on the specific examination style of LEE, HOI YAN NMN to navigate the 1 pending office action effectively. The outcome of the company's current patent efforts depends entirely on the interactions within this specific administrative channel and the standards of the Biotechnology & Pharmaceuticals division.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17598491 | COMPOSITIONS OF DISPERSED PHASE FOR PREPARATION OF APIXABAN-LOADED MICROSPHERES AND BIOCOMPATIBLE POLYMER-BASED APIXABAN-LOADED MICROSPHERES PREPARED THEREFROM | LEE, HOI YAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17598491 | COMPOSITIONS OF DISPERSED PHASE FOR PREPARATION OF APIXABAN-LOADED MICROSPHERES AND BIOCOMPATIBLE POLYMER-BASED APIXABAN-LOADED MICROSPHERES PREPARED THEREFROM | LEE, HOI YAN NMN | 1693 | §103 | Final Rejection | — | Pending | Sep 27, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHlb Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hoi Yan Nmn Lee has the most, with 1 of Hlb Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
